Antimicrobial resistance a big danger to public health worldwide
06.02.2014
The venture leader BioVersys, a privately held Swiss biopharmaceutical company located in Basel focused on antibiotic resistance, will collaborate with the Swedish company SARomics Biostructures to fight against multidrug-resistant bacterial infections.
 Marcel Tigges, CSO and Marc Gitzinger, CEO from BioVersys
|
 |
Antimicrobial resistance is a big danger to public health worldwide. Just a few products are in clinical development therefore the problem needs to be adequately addressed. The goal of the so called SARTRIC project is to restoring the antibiotic activity by finding a way to block the transcriptional activation of resistance genes with small molecules so that drugs that are already on the market will work on the resistant diseases again. Both companies will combine technology modules, expertise and resources to drive the drug development process of initial hit molecules towards fully characterized lead molecules that qualify for preclinical testing. The international project is supported by the European initiative Eurostars.
“It is a great pleasure to see the synergies between our two companies bearing fruit in an international collaboration with the support and funding of EUROSTARS” said CSO at BioVersys Marcel Tigges. Dr. Björn Walse, CEO at SARomics Biostructures add: “We are excited to collaborate with BioVersys on this potentially game-changing approach that addresses a high unmet medical need.”
More about Eurostars
Eurostars is a joint programme between more than 30 EUREKA member countries and the European Union. It supports research-performing small and medium enterprises, which develop innovative products, processes and services, to gain competitive advantage. Eurostars does this by providing funding for transnational innovation projects; the products of which are then rapidly commercialized.
More about BioVersys
The company focuses on the research and development of new drugs and compounds that switch off drug resistance within bacterial pathogens and thus restore the efficacy of existing antibiotics. The Team and the technology of BioVersys have already received multiple awards, such as venture kick, the Heuberger Winterthur Jungunternehmerpreis 2009 and the Swiss TB Award.
More about SARomics Biostructures
The firm is a technology driven research located in the Medicon Valley region of southern Sweden. SARomics advanced structural biology platform and expertise in structure-based drug design is applied to a number of innovative early stage drug discovery projects as well as in fee for service projects for clients.The above project is the third consecutive EU financed project awarded to SARomics. The other two, TAKTIC and KINOMED are kinase drug discovery projects for oncology indications.
“It is a great pleasure to see the synergies between our two companies bearing fruit in an international collaboration with the support and funding of EUROSTARS” said CSO at BioVersys Marcel Tigges. Dr. Björn Walse, CEO at SARomics Biostructures add: “We are excited to collaborate with BioVersys on this potentially game-changing approach that addresses a high unmet medical need.”
More about Eurostars
Eurostars is a joint programme between more than 30 EUREKA member countries and the European Union. It supports research-performing small and medium enterprises, which develop innovative products, processes and services, to gain competitive advantage. Eurostars does this by providing funding for transnational innovation projects; the products of which are then rapidly commercialized.
More about BioVersys
The company focuses on the research and development of new drugs and compounds that switch off drug resistance within bacterial pathogens and thus restore the efficacy of existing antibiotics. The Team and the technology of BioVersys have already received multiple awards, such as venture kick, the Heuberger Winterthur Jungunternehmerpreis 2009 and the Swiss TB Award.
More about SARomics Biostructures
The firm is a technology driven research located in the Medicon Valley region of southern Sweden. SARomics advanced structural biology platform and expertise in structure-based drug design is applied to a number of innovative early stage drug discovery projects as well as in fee for service projects for clients.The above project is the third consecutive EU financed project awarded to SARomics. The other two, TAKTIC and KINOMED are kinase drug discovery projects for oncology indications.